Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
09:35am, Tuesday, 17'th Mar 2026
Sector exposure, yield, and fund size set these two small-cap value ETFs apart-see how these factors could impact your investment approach.
The S&P 500's 3 Best-Performing Stocks so far in 2026
08:24am, Monday, 16'th Mar 2026
Fear is dominating global markets right now. With geopolitical tensions intensifying in the Middle East and capital rotating out of equities, the S&P 500 ETF NYSEARCA: SPY is down about 2% year to dat
Moderna (MRNA) Declines More Than Market: Some Information for Investors
06:45pm, Friday, 13'th Mar 2026
In the most recent trading session, Moderna (MRNA) closed at $52.56, indicating a -1.55% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11:40am, Tuesday, 10'th Mar 2026
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture
08:40am, Tuesday, 10'th Mar 2026
With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
01:35pm, Monday, 09'th Mar 2026
Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
01:32pm, Monday, 09'th Mar 2026
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his positio
Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April
06:02pm, Friday, 06'th Mar 2026
Moderna stock jumped late Friday on reports the FDA's top vaccine official, Vinay Prasad, will step down amid mounting industry concerns.
FDA reversals leave investors worrying about the fates of other experimental drugs
11:33am, Friday, 06'th Mar 2026
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co
These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next
08:30am, Friday, 06'th Mar 2026
Wall Street's read on three of 2026's most volatile names—Moderna (NASDAQ: MRNA), Strategy (NASDAQ: MSTR), and Trade Desk (NASDAQ: TTD)—tells three very different stories.
Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn
08:41am, Thursday, 05'th Mar 2026
Investors who closely watch the healthcare sector are keeping an eye on Moderna ( NASDAQ:MRNA ) as its shares are up 12% over the past week and 95% year-to-date, trading near $56.67 as of March 4, 202
Market Today: Wall St. Rebounds; NVDA, AMZN, TGT in Focus
05:35pm, Wednesday, 04'th Mar 2026
Guru Stock PicksFairholme Fund has made the following transactions:Reduce in JOE by 0.23%David Tepper has made the following transactions:Reduce in WHR by 18.41
The Sun Will Shine On Moderna Again - Initiating With A Buy
03:16pm, Wednesday, 04'th Mar 2026
Moderna is initiated at a buy rating, as multiyear growth drivers and robust 2026 guidance signal a turnaround. mNEXSPIKE approvals, flu and combo vaccines, and mRNA therapeutics expansion underpin Mo
Stock Market Today: Major Indexes Surge After Sell-Off; Bitcoin, Crypto-Tied Stocks Soar
02:30pm, Wednesday, 04'th Mar 2026
Major stock indexes jumped Wednesday, a day after they fell but finished well above early lows, as Middle East fighting entered its fifth day.
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
11:05am, Wednesday, 04'th Mar 2026
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP tec
